福森药业(01652)：“二甲双胍恩格列净片(I)”获批上市

Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its "Metformin Empagliflozin Tablets (I)", which is intended for the treatment of type 2 diabetes in adults, enhancing blood sugar control in patients already on metformin and empagliflozin therapy [1] Company Summary - The "Metformin Empagliflozin Tablets (I)" is a combination formulation of metformin and empagliflozin, which works synergistically to improve glycemic control compared to standard monotherapy [1] - The company views this product as a significant addition to its diabetes treatment portfolio, providing more options for patients suffering from diabetes [1]